Remove IPO Remove M&A Remove Pharmaceutical
article thumbnail

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

Although 2022 saw a general decline in M&A activity in the life sciences industry compared to 2021’s frenetic pace (when deal volume was up 52% from 2020 ), life sciences deal flow in 2022 on balance remained strong despite the headwinds. Let’s dig in. Let’s dig in.

M&A 40
article thumbnail

Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024

Cooley M&A

In a subdued year for global M&A, deal-making in the life sciences industry came in waves, with a busy fourth quarter generating cautious optimism heading into 2024. Big pharma dominated life sciences M&A, with more than two-thirds (69%) of M&A investment coming from big pharma, compared to just 38% in 2022.

M&A 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Best Stocks: Three healthcare names to ponder including a biotech back to levels not seen in a decade

CNBC: Investing

Josh here — The healthcare sector has entered the chat. There are 12 healthcare names now on our Best Stocks list as of the end of last week. I'll show you a few of these set-ups below and then Sean's going to share some fundamentals for these healthcare firms. So far, so good as ALNY grew revenue to $2.25

article thumbnail

How Common are Postmerger Divestitures of Acquired Company Units?

M&A Leadership Council

Fundamentals of M&A: An Excerpt from The Art of M&A Book Series. By Alexandra Reed Lajoux, Board of M&A Standards/Founding Principal at CapEx . How Common are Postmerger Divestitures of Acquired Company Units? . It depends on how long a timeline for divestiture you are considering. What is a sell-off? .

article thumbnail

Shareholders vs. Stakeholders - Understanding Corporate Responsibilities

Peak Frameworks

For example, in the 2012 Facebook IPO, common shareholders gained exposure to the tech giant's fortunes, while also securing a say in corporate matters. The distinction between them is crucial for understanding a company's obligations, its strategy, and the interplay of interests within its ecosystem. What is a Shareholder?

article thumbnail

The Full Guide to Healthcare Private Equity, from Careers to Contradictions

Mergers and Inquisitions

When you hear the words “healthcare private equity,” two thoughts probably come to mind: Wait a minute, isn’t healthcare a risky/growth-oriented sector? Why do PE firms operate there? Don’t they need companies with stable cash flows? In most of the world, healthcare is either government-run or a mixed public/private sector. For example, in the U.S.,

article thumbnail

Spot Cyber & IT Challenges Through Improved Due Diligence

M&A Leadership Council

Insights & Advice: An Interview with Two Experts By Mark Herndon, Chairman Emeritus, M&A Leadership Council Cybersecurity and IT due diligence has become one of the most challenging, and also one of the most critical areas of due diligence in any environment. Tell us more about that. What is the business trying to accomplish?

IT 52